21JAN20 Mesnchymal Stem Cells MSC-1
Clinical Capabilities

Therapeutic Pipeline

Better Translating Discoveries into Therapies

At REPROCELL, we are developing new strategies for treating rare central nervous system diseases. We currently have two therapeutic products in our clinical pipeline, one made from Glial-restricted Progenitor Cells (GRPs) and another from Mesenchymal Stem Cells (MSCs). 

Our GRP therapeutic is being developed in the United States, while the MSC being trailed in Taiwan, Japan, Korea, and the USA. Sign up for our clinical news updates to receive the latest information about these therapeutics, or find out more information below. 


21JAN20 Glial Restricted Progenitor Cells GRPjpg

Q-cell GRP Cell Therapy

Our iPSC-GRPs are being developed in collaboration with Q Therapeutics Inc. in the United States. Preclinical iPSC-GRP research is currently taking place in our cGMP cell processing suite, located at the Life Innovation Center in Japan. So far, these therapeutics have demonstrated efficacy in the treatment of Amyotrophic Lateral Sclerosis and Transverse myelitis.

Learn more about Q-cell GRP Cell Therapy →

21JAN20 Mesnchymal Stem Cells MSC-3

Stemchymal MSC therapy

Stemchymal® is an allogenic cellular therapy derived from Mesenchymal stem cells. The therapeutic is being developed by Steminent Biotherapeutics, whom REPROCELL have an exclusive co-development and sale agreement with in Japan. Results from early stage clinical trials suggest that Stemchymal is safe for intravenous administration in humans. Phase II clinical trials are now underway to estimate efficacy of the treatment in patients with Spinocerebellar Ataxia. 

Learn more about Stemchymal →